Sinco Pharmaceuticals Holdings Management
Management criteria checks 4/4
Sinco Pharmaceuticals Holdings' CEO is Min Jin, appointed in Mar 2023, has a tenure of 1.83 years. total yearly compensation is CN¥1.96M, comprised of 94.6% salary and 5.4% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth HK$3.49M. The average tenure of the management team and the board of directors is 2 years and 5.3 years respectively.
Key information
Min Jin
Chief executive officer
CN¥2.0m
Total compensation
| CEO salary percentage | 94.6% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Shares Climb 27% But Its Business Is Yet to Catch Up
Jan 09
Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop
Nov 20What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You
Oct 04Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Aug 16Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings
Apr 02Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks
Mar 08Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Jun 26Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥47m |
| Mar 31 2024 | n/a | n/a | CN¥44m |
| Dec 31 2023 | CN¥2m | CN¥2m | CN¥42m |
| Sep 30 2023 | n/a | n/a | CN¥35m |
| Jun 30 2023 | n/a | n/a | CN¥27m |
| Mar 31 2023 | n/a | n/a | CN¥48m |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥69m |
Compensation vs Market: Min's total compensation ($USD268.87K) is about average for companies of similar size in the Hong Kong market ($USD229.76K).
Compensation vs Earnings: Min's compensation has been consistent with company performance over the past year.
CEO
Min Jin (46 yo)
1.8yrs
Tenure
CN¥1,959,000
Compensation
Mr. Min Jin is Chief Accountant since August 17, 2023 and Secretary since December 21, 2023 at Nanjing Tanker Corporation. He was Co-Chief Executive Officer at Sinco Pharmaceuticals Holdings Limited since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.8yrs | CN¥7.10m | 51.65% HK$ 267.7m | |
| Chief Executive Officer | 1.8yrs | CN¥1.96m | 0.67% HK$ 3.5m | |
| Executive Director | no data | CN¥1.09m | no data | |
| Executive Vice Chairman | less than a year | no data | no data | |
| Chief Financial Officer | 9.6yrs | no data | no data | |
| Company Secretary | 5.3yrs | no data | no data | |
| President of Sichuan Sinco Pharmaceuticals Co. Ltd. | 2.2yrs | no data | no data |
2.0yrs
Average Tenure
44yo
Average Age
Experienced Management: 6833's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.8yrs | CN¥7.10m | 51.65% HK$ 267.7m | |
| Executive Director | 1.8yrs | CN¥1.09m | no data | |
| Executive Vice Chairman | less than a year | no data | no data | |
| Independent Non-Executive Director | 6.2yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 8.9yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 8.9yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 4.3yrs | CN¥300.00k | no data | |
| Non-Executive Director | less than a year | no data | no data |
5.3yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 6833's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 06:50 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinco Pharmaceuticals Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Milo Liu | China Merchants Securities (HK) Co., Ltd |